ResMed (ASX:RMD) share price on watch following Q3 results

The ResMed Inc. (ASX:RMD) share price will be one to watch closely on Friday following the release of its third quarter results this morning…

| More on:
A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc. (ASX: RMD) share price will be one to watch closely this morning.

This follows the release of the sleep treatment focused medical device company's third quarter results.

How did ResMed perform in the third quarter?

For the three months ended 31 March, ResMed posted revenue of US$768.8 million.

While this is down 0.1% from US$769.5 million in the prior corresponding period, it is worth noting that the prior corresponding period was boosted significantly by strong demand for ventilators at the height of the pandemic.

Positively, a reduction in selling, general, and administrative expenses offset this and underpinned a 3% increase in operating profit to US$223.4 million.

On the bottom line, earnings per share came in 1% higher than the prior corresponding period at US$1.30.

ResMed's CEO, Mick Farrell, said: "Our March 2021 quarter results reflect the ongoing recovery of core patient flow across our business, while we anniversary the $35 million of incremental COVID-19 revenue in the same quarter last year. Excluding the COVID19 revenue from the March 2020 quarter, we achieved positive revenue growth on both a headline and constant currency basis."

How did ResMed's businesses perform?

Revenue in the U.S., Canada, and Latin America region (excluding Software as a Service) grew by 2% during the quarter. This was driven by strong sales across mask products, partially offset by lower device sales, including decreased demand for ventilators.

Revenue in Europe, Asia, and other markets declined by 13% on a constant currency basis, primarily driven by lower device sales. This includes decreased demand for ventilators due to COVID-19, and flat sales in its mask product portfolio.

Software as a Service revenue increased by 5% due to continued growth in resupply service offerings and stabilising patient flow in out-of-hospital care settings.

ATO dispute

Mr Farrell also revealed that progress has been made with its long-running dispute with the Australian Tax Office.

He explained: "During the quarter we also made substantial progress toward resolving our long-running dispute with the Australian Tax Office. Although we do not have a final agreement, we have taken a reserve of US$255 million, reflecting our estimate of the net impact of a potential settlement. Our next steps are to agree on the final terms of a resolution giving us clarity for the future."

Outlook

No guidance was given for the remainder of the year. However, management appears confident in its growth trajectory.

"Going forward, we see accelerated awareness of the importance of respiratory health, growing adoption of digital health, and an increased focus on the importance of healthcare delivered at home. We are confident in accelerated growth in patient flow, and ongoing progress toward our goal of improving 250 million lives in out-of-hospital healthcare in 2025," concluded Mr Farrell.

The ResMed share price is up 17% over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Broker Notes

2 of the best ASX shares to buy in 2025

Bell Potter is feeling bullish on these shares as the new year approaches.

Read more »

A happy man and woman on a computer at Christmas, indicating a positive trend for retail shares.
Share Market News

5 things to watch on the ASX 200 on Tuesday

Will the market give investors a little Christmas present today?

Read more »

Young boy in business suit punches the air as he finishes ahead of another boy in a box car race.
Opinions

Why I think these 2 ASX 300 stocks will beat the market in 2025

I’m very optimistic about a few ASX growth shares.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why EML, GQG Partners, IGO, and Integrated Research shares are sinking today

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of…

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why EOS, News Corp, Polynovo, and Pro Medicus shares are roaring higher today

These shares are starting the week positively. But why?

Read more »

A couple stares at the tv in shock, one holding the remote up ready to press.
Mergers & Acquisitions

Telstra share price climbs amid $3.4b Foxtel sale

Who is buying the Foxtel business? Let's find out.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Share Market News

Brokers say these ASX 200 growth stocks could rise 50% to 70%

Analysts think these shares could be dirt cheap and destined to generate big returns.

Read more »

Two people having a meeting using a laptop and tablet to discuss Seven West Media's balance sheet
Broker Notes

Why these ASX shares could be top SMSF options in 2025

Analysts are bullish on these high-quality shares. Let's find out why.

Read more »